QLT's head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company's products and developments, please visit our web site at www.qltinc.com .

Visudyne® is a registered trademark of Novartis AG.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

The QLT Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6933

Certain statements in this press release constitute "forward-looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to: statements concerning the return of capital and the development plans for our Oral Retinoid program (QLT091001); statements concerning the potential divestment of the punctal plug drug delivery system program (PPDS); and statements which contain language such as: "assuming," "prospects," "goal," "future," "projects," "potential," "believes," "expects"; "hopes" and "outlook." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: risks and uncertainties about our ability to return capital to our shareholders on a favorable tax basis or at all and to successfully develop our Oral Retinoid program (QLT091001); risks and uncertainties related to the timing and our ability to divest the PPDS on terms favorable to us or at all; risks and uncertainties concerning the impacts that QLT's strategic initiatives will have on the market price of our securities; uncertainties relating to our development plans, timing and results of the clinical development and commercialization of our products and technologies; assumptions related to continued enrollment trends, efforts and success, and the associated costs of these programs; outcomes for our clinical trials (including our punctal plug technology and our synthetic retinoid program) may not be favorable or may be less favorable than interim/preliminary results and/or previous trials; there may be varying interpretations of data produced by one or more of our clinical trials; the timing, expense and uncertainty associated with the regulatory approval process for products to advance through development stages; risks and uncertainties associated with the safety and effectiveness of our technology; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; the Company's future operating results are uncertain and likely to fluctuate; currency fluctuations; and general economic conditions and other factors described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law. 
CONTACT: QLT Inc. Contacts:         Investor & Media Relations         Andrea Rabney or David Pitts         Argot Partners         212-600-1902         andrea@argotpartners.com         david@argotpartners.com

company logo

If you liked this article you might like

Auxilium Pharmaceuticals' Slow Response to Endo Troubles Investors

8 More ETFs Join Deathwatch in December

Alternative Funds for Volatile Markets

Eyetech Gains Despite Loss

Eyetech Gains Despite Loss

Eyetech Drug Reviewed by FDA Panel

Eyetech Drug Reviewed by FDA Panel